Natco Pharma Limited has informed the Exchange regarding a press release dated July 24, 2025, titled "NATCO Pharma Limited, API unit in Mekaguda Receives Establishment Inspection Report (EIR) from U.S. FDA".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Smallcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma's Active Pharmaceutical Ingredient (API) manufacturing facility at Mekaguda, Hyderabad has received the Establishment Inspection Report (EIR) from the U.S. FDA, closing out an inspection that took place from June 9–13, 2025. The facility had received only 1 observation in a Form-483, which was classified as 'Voluntary Action Indicated' (VAI) — a positive outcome that means no further regulatory action is required. The EIR issuance confirms that the inspection is formally closed and the facility is in good standing with the U.S. regulator. The Mekaguda plant is part of Natco's network of 9 manufacturing sites that supply generic and specialty pharmaceuticals to 50+ global markets.
Positive for shareholders — the clean VAI classification and EIR clearance remove regulatory uncertainty for a key API facility that supplies the lucrative U.S. market, supporting continued exports and future product approvals from this site.